JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed

Ionis Pharmaceuticals once had AstraZeneca involved with and spied a bright future for PCSK9 inhibitor ION449. Now, after the U.K. pharma backed out last year, CEO Brett Monia, Ph.D., thinks the drug may have missed its shot.